- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01915576
Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients
A Phase I, Multi-center, Non-randomized, Open-label, Dose Escalation Design Study to Characterize Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY 1125976 in Subjects With Advanced Solid Tumors
This is the first study where BAY1125976 is given to humans. Patients (all comers) will receive the study drug treatment in a dose-escalation scheme (no placebo group) to determine the safety, tolerability and maximum tolerated dose (MTD) of BAY1125976. The relative bioavailability of liquid service formulation and tablets will be determined.
After the MTD is defined breast cancer patients with and without AKT1 mutation will be treated.
The study will also assess the pharmacokinetics, biomarker status, pharmacodynamic parameters and tumor response of BAY1125976.
BAY1125976 will be given daily as single oral application. Treatment will be stopped if the tumor continues to grow, if side effects, which the patient cannot tolerate, occur or if the patient decides to exit treatment.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 1
Contacten en locaties
Studie Locaties
-
-
Baden-Württemberg
-
Heidelberg, Baden-Württemberg, Duitsland, 69120
-
-
-
-
-
Villejuif Cedex, Frankrijk, 94805
-
-
-
-
California
-
Santa Monica, California, Verenigde Staten, 90404
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02215
-
-
Missouri
-
St. Louis, Missouri, Verenigde Staten, 63110
-
-
Texas
-
Houston, Texas, Verenigde Staten, 77030
-
-
-
-
Sankt Gallen
-
St. Gallen, Sankt Gallen, Zwitserland, 9007
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- For dose escalation cohorts: Subjects with advanced, histologically or cytologically confirmed solid tumors are eligible. Subjects' tumors (all comers) must be refractory to standard treatment with no standard therapy available, or subjects actively refuse any treatment, which would be regarded standard. In addition, the investigator must judge the experimental treatment as clinically and ethically acceptable
- For expansion cohort only: Subjects with histologically or cytologically proven metastatic breast cancer (with and without AKT1 E17K (G49A) mutation) or subjects with known AKT1 E17K (G49A) mutation in any other advanced solid tumor with at least one line of chemotherapy in the metastatic setting and not amenable to surgery with curative intent
- Subjects must have measurable disease (Response evaluation criteria in solid tumors (RECIST 1.1)
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0 - 2
- Bone marrow, liver and renal functions as assessed by adequate laboratory methods to be conducted within 7 days prior to starting study treatment
- Subjects must provide tumor biopsies before treatment
- Recovery to CTCAE (Common Terminology Criteria for Adverse Events Version 4.03) Grade 0 or Grade 1 or recovery to baseline preceding the prior treatment of any previous drug / procedure-related toxicity (except alopecia, anemia, and hypothyroidism)
Exclusion Criteria:
- History of cardiac disease including congestive heart failure > New York Heart Association (NYHA) Class II
- Subjects with type 1 or type 2 diabetes mellitus
- Subjects with fasting glucose >125 mg/dL in 2 independent measurements or glycated hemoglobin (HbA1c) ≥ 7%
- Moderate and severe hepatic impairment, i.e. Child-Pugh B or C
- Active infections of CTCAE (Common Terminology Criteria for Adverse Events Version 4.03) Grade >2 or infections of CTCAE Grade 2 not responding to therapy
- Symptomatic metastatic brain or meningeal tumors unless the patient is > 3 months from definitive therapy, has a negative imaging study within 4 weeks of study entry and is clinically stable with respect to the tumor at the time of study entry.
- Subjects undergoing renal dialysis
- Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study except cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis & T1) or any cancer curatively treated > 3 years prior to study entry
- Autologous bone marrow transplant or stem cell rescue within 4 months of study entry
- Treatment with oral steroids (dose ≥ 10 mg/day of methylprednisolone or equivalent)
- Clinically relevant findings in the ECG such as a second- or third-degree AV block, prolongation of the QRS complex over 120 msec or of the QTcF-interval over 450 msec
- Acute toxic effects of previous anticancer chemotherapy or immunotherapy have to be normalized to CTCAE Grade equal or lower than 1 (excluding alopecia)
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: BAY1125976 [once daily, dose-esc.]
Oral administration once daily.
Starting dose is 10 mg and will be escalated depending on any dose-limiting toxicities
|
Oral administration once daily.
Starting dose is 10 mg and will be escalated depending on any dose-limiting toxicities
Oral administration twice daily.
Starting dose is 40mg twice daily and will be escalated depending on any dose-limiting toxicities
Oral administration of the defined MTD which shows optimal safety, PK profile, PD target inhibition and preliminary efficacy (once daily or twice daily) in different patient groups
|
Experimenteel: BAY1125976 [twice daily, dose-esc.]
Oral administration twice daily.
Starting dose is 40mg twice daily and will be escalated depending on any dose-limiting toxicities
|
Oral administration once daily.
Starting dose is 10 mg and will be escalated depending on any dose-limiting toxicities
Oral administration twice daily.
Starting dose is 40mg twice daily and will be escalated depending on any dose-limiting toxicities
Oral administration of the defined MTD which shows optimal safety, PK profile, PD target inhibition and preliminary efficacy (once daily or twice daily) in different patient groups
|
Experimenteel: BAY1125976 [MTD]
Oral administration of the defined MTD which shows optimal safety, PK profile, PD target inhibition and preliminary efficacy (once daily or twice daily) in different patient groups
|
Oral administration once daily.
Starting dose is 10 mg and will be escalated depending on any dose-limiting toxicities
Oral administration twice daily.
Starting dose is 40mg twice daily and will be escalated depending on any dose-limiting toxicities
Oral administration of the defined MTD which shows optimal safety, PK profile, PD target inhibition and preliminary efficacy (once daily or twice daily) in different patient groups
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Number of participants with adverse events as a measure of safety and tolerability
Tijdsspanne: up to 2 years
|
up to 2 years
|
Maximum tolerated dose (MTD) of BAY1125976
Tijdsspanne: up to 2 years
|
up to 2 years
|
Area under the plasma concentration vs time curve from zero to infinity after single (first) dose
Tijdsspanne: at pre-dose and 0.5, 1, 2, 4, 6, 8, 12 and 24 hours post-dose
|
at pre-dose and 0.5, 1, 2, 4, 6, 8, 12 and 24 hours post-dose
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Food effect assessment
Tijdsspanne: up to 2 years
|
The effect of a high-fat, high-calorie meal on the pharmacokinetic parameters of BAY1125976 will be determined in 6 - 9 subjects in the MTD dose level or a lower dose level receiving the tablet for the cohort of the dose escalation part.
|
up to 2 years
|
Tumor response will be evaluated based on Response Evaluation Criteria in Solid Tumors (RECIST) definitions
Tijdsspanne: up to 2 years
|
up to 2 years
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Andere studie-ID-nummers
- 16447
- 2012-004671-39 (EudraCT-nummer)
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .